Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06008977 · ClinicalTrials.gov registry record · NA

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

A NA study of Cutaneous Melanoma and Merkel Cell Carcinoma, sponsored by AdventHealth Translational Research Institute.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06008977: Recruiting NA study of Cutaneous Melanoma and Merkel Cell Carcinoma, sponsored by AdventHealth Translational Research Institute.

NCT06008977 is a NA study of Cutaneous Melanoma and Merkel Cell Carcinoma that is actively recruiting participants, run by AdventHealth Translational Research Institute. The registered enrollment target is 20 participants, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06008977, a NA study of Cutaneous Melanoma and Merkel Cell Carcinoma, is actively recruiting participants, sponsored by AdventHealth Translational Research Institute.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel cell carcinoma, scheduled to receive checkpoint blockade immunotherapy, and ii) preliminary data on the impact of a day-of-therapy exercise intervention.

Primary Outcome

For patients treated in the adjuvant setting. Total study duration is dependent upon oncology therapy. Recurrence-free survival will be assessed.

Interventions

  • OTHER Exercise Test

Study Locations (1)

Florida

  • AdventHealth Translational Research Institute - Orlando

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-06-03
Est. Completion 2025-12
Phase NA

What NCT06008977 shows while recruiting

NCT06008977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Exercise Test is the first listed.

NCT06008977 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06008977 about?

NCT06008977 is a clinical study titled "Exercise to Boost Response to Checkpoint Blockade Immunotherapy". The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel cell carcinoma, scheduled to receive checkpoint blockade immunotherapy, ...

What is the current status of trial NCT06008977?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-06-03. Estimated completion is 2025-12.

What conditions does trial NCT06008977 study?

This clinical trial studies the following conditions: Cutaneous Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma.

What interventions are being tested in trial NCT06008977?

The interventions under investigation include: Exercise Test (OTHER).

Who is sponsoring clinical trial NCT06008977?

This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06008977 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cutaneous Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06008977's enrollment target sits among peer trials

20 25th of 30 higher than 4 of 30 other Cutaneous Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cutaneous Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06008977, the US trial registry maintained by the National Library of Medicine. NCT06008977 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.